-
The Western Journal of Medicine Oct 1995
Topics: Anti-Asthmatic Agents; Asthma; Drug Resistance; Glucocorticoids; Humans; Prednisone
PubMed: 7483594
DOI: No ID Found -
British Medical Journal Mar 1973
Topics: Herpes Zoster; Humans; Neuralgia; Prednisone
PubMed: 4692724
DOI: 10.1136/bmj.1.5854.679-b -
British Medical Journal Nov 1967
Topics: Female; Humans; Muscular Diseases; Prednisone; Sarcoidosis
PubMed: 6055735
DOI: 10.1136/bmj.4.5577.465 -
Journal of Ovarian Research Apr 2023Prednisone is one of the most used synthetic glucocorticoids during pregnancy. Epidemiological investigations suggested that prenatal prednisone therapy could affect...
BACKGROUND
Prednisone is one of the most used synthetic glucocorticoids during pregnancy. Epidemiological investigations suggested that prenatal prednisone therapy could affect fetal development, but systematic studies on its effects on ovarian development and the "toxic effect window" remained scarce.
METHODS
In this study, by simulating clinical application characteristics, Kunming mice were given prednisone by oral gavage with different doses (0.25 or 1.0 mg/kg·d) or at different time gestational days (GD) (GD0-9, GD10-18, or GD0-18). Blood and ovaries of fetal mice were collected on GD18, and the serum estradiol level and the related function indexes of ovarian granulosa cells and oocytes were detected.
RESULTS
Compared with the control group, prenatal prednisone exposure (PPE) induced pathological injury and enhanced cell proliferation in fetal mice ovary. Furthermore, the expression of steroid synthesis functional genes in pre-granulosa cells, the oocyte function markers, and developmentally related genes was enhanced with different doses or at different time of PPE. The Hippo signaling was activated in the fetal ovary of PPE groups. The above changes were most significant in the low or high-dose and full-term PPE groups.
CONCLUSION
PPE caused various cell developmental toxicity in the fetal ovary, especially in the low or high-dose, full-term exposure groups. The potential mechanism might be related to the activation of the Hippo signaling pathway.
Topics: Mice; Pregnancy; Female; Animals; Estradiol; Prednisone; Ovary; Oocytes
PubMed: 37038227
DOI: 10.1186/s13048-023-01148-8 -
Journal of Veterinary Internal Medicine 2009The coadministration of prednisone and ultralow-dose aspirin has been recommended for the management of various diseases, but the safety of this combination in dogs has... (Randomized Controlled Trial)
Randomized Controlled Trial
BACKGROUND
The coadministration of prednisone and ultralow-dose aspirin has been recommended for the management of various diseases, but the safety of this combination in dogs has not been studied.
HYPOTHESES
The gastroduodenal lesions associated with prednisone and ultralow-dose aspirin administration will be similar to those caused by prednisone alone, but both treatments will result in more severe lesions than placebo.
ANIMALS
Eighteen healthy adult purpose-bred dogs.
METHODS
Randomized, blinded, placebo-controlled study of 3 treatment groups for 27 days: placebo, prednisone, and prednisone and aspirin. Gastroduodenoscopy was performed before and on days 5, 14, and 27 of treatment and mucosal lesions scores were assigned. Mucosal lesion scores were compared by a Kruskal-Wallis test. Clinical signs were compared by the Friedman's chi-square test (significance at P < .05).
RESULTS
There were no significant differences in the gastroduodenal lesion scores among groups, or within groups at any time during the study. Significantly more dog-days of diarrhea occurred in the prednisone and aspirin group during treatment, compared with baseline. No significant differences in clinical signs were found among any of the groups.
CONCLUSION
The concurrent use of prednisone and ultralow-dose aspirin did not increase the severity of gastroduodenal lesions compared with prednisone or placebo. Coadministration of prednisone and ultralow-dose aspirin increases the frequency of mild, self-limiting diarrhea in some dogs.
Topics: Animals; Aspirin; Dogs; Female; Gastric Mucosa; Gastrointestinal Diseases; Intestinal Mucosa; Male; Prednisone
PubMed: 19422469
DOI: 10.1111/j.1939-1676.2009.0312.x -
Journal of the American Veterinary... Feb 2002To evaluate the effect of prednisone alone, compared with a combination of prednisone and vincristine, on platelet counts in bleeding dogs with severe primary... (Clinical Trial)
Clinical Trial Comparative Study
OBJECTIVE
To evaluate the effect of prednisone alone, compared with a combination of prednisone and vincristine, on platelet counts in bleeding dogs with severe primary immune-mediated thrombocytopenia (IMT).
DESIGN
Prospective case study.
ANIMALS
24 dogs with severe primary IMT PROCEDURE: All dogs received immunosuppressive doses of prednisone (1.5 to 2 mg/kg [0.7 to 0.9 mg/lb] of body weight, PO, q 12 h). In addition, 12 dogs received a single dose of vincristine (0.02 mg/kg [0.01 mg/lb], IV). Platelet count, transfusion requirement, and outcome were monitored. A response was defined as an increase in platelet count to > or = 40,000/microl. Dogs in the prednisone group that failed to respond received 1 dose of vincristine on day 7.
RESULTS
Dogs that received prednisone and vincristine had a significantly faster increase in platelet count to > or = 40,000 platelets/microl than dogs that received prednisone alone (mean +/- SD, 4.9 +/- 1.1 vs 6.8 +/- 4.5 days, respectively). A similarly rapid response was observed in dogs that received vincristine on day 7 after treatment with prednisone alone failed. Furthermore, duration of hospitalization was reduced in the vincristine group, compared with the prednisone group (5.4 +/- 0.3 vs 7.3 +/- 0.5 days, respectively). No adverse effects attributable to vincristine were observed in any dog.
CONCLUSIONS AND CLINICAL RELEVANCE
Administration of combined vincristine and prednisone is associated with more rapid increase in platelet numbers and shortened duration of hospitalization in dogs with IMT, compared with use of prednisone alone. Early use of vincristine seems warranted in dogs with severe primary IMT.
Topics: Animals; Blood Platelets; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Glucocorticoids; Male; Platelet Count; Prednisone; Prospective Studies; Thrombocytopenia; Treatment Outcome; Vincristine
PubMed: 11860242
DOI: 10.2460/javma.2002.220.477 -
Scientific Reports Jun 2024Previous studies showed tacrolimus monotherapy and dual therapy with tacrolimus and prednisone as effective treatment modalities in managing membranous nephropathy.... (Comparative Study)
Comparative Study
Previous studies showed tacrolimus monotherapy and dual therapy with tacrolimus and prednisone as effective treatment modalities in managing membranous nephropathy. However, few studies have compared these therapeutic regimens. The patients were divided into two groups based on the treatment regimen: (1) tacrolimus and prednisone dual therapy (T + P group, n = 67) treatment group; and (2) tacrolimus monotherapy (T group, n = 65) or the control group. Propensity matching method and subgroup analysis to eliminate the bias in the relationship between the treatment regimen and the outcomes. The mean remission times were 20.33 ± 2.75 weeks at T group and 9.50 ± 1.81 weeks at T + P group. The T group had a remission rates of 73.33, 76.66 and 66.66% at 12weeks, 24weeks and 48weeks, while the T + P group had a remission rate of 81.66, 86.66, 91.66%; At the follow-up of 48 weeks, the relapse rate for the T group was 21.66%, and that for the T + P group was 5%. The anti-PLA2R ab is positive and therapy may be the independent risk factors for predicting remission. Tacrolimus and low-dose prednisone dual therapy is efficacious in managing MN and lowers the recurrence rate in clinical practice.
Topics: Humans; Tacrolimus; Glomerulonephritis, Membranous; Prednisone; Male; Female; Middle Aged; Retrospective Studies; Drug Therapy, Combination; Immunosuppressive Agents; Adult; Treatment Outcome; Aged; Remission Induction
PubMed: 38902302
DOI: 10.1038/s41598-024-64661-w -
American Journal of Hematology Apr 2015
Topics: Aged; Diagnosis, Differential; Eosinophils; Female; Glucocorticoids; Humans; Hypereosinophilic Syndrome; Leukocyte Count; Prednisone; Treatment Outcome
PubMed: 25294166
DOI: 10.1002/ajh.23869 -
Thorax May 1988To examine the effect of corticosteroids on bronchial hyperresponsiveness, a randomised, double dummy, single blind crossover study was performed in 18 subjects with... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
To examine the effect of corticosteroids on bronchial hyperresponsiveness, a randomised, double dummy, single blind crossover study was performed in 18 subjects with chronic asthma, comparing the effect of three weeks' treatment with inhaled beclomethasone dipropionate, 1200 micrograms daily, and oral prednisone 12.5 mg daily. The 12 week study began with a three week run in period of baseline treatment, which was continued unchanged throughout the study, and the two treatment periods were separated by a three week washout period. Patients kept daily Airflometer readings and attended the laboratory every three weeks for spirometry and a histamine inhalation test for determining the provocative dose of histamine causing a 20% fall in FEV1 (PD20). The mean FEV1 at the start was 1.9 litres (56% predicted). There was no significant change in PD20 with prednisone treatment, the mean PD20 being 0.56 and 0.59 mumol before and after treatment. There was, however, a significant improvement in PD20 with beclomethasone dipropionate treatment, the geometric mean PD20 being 0.38 and 1.01 mumol before and after treatment (p less than 0.001). There was a small but significant improvement in mean FEV1 after beclomethasone dipropionate treatment--from 1.9 to 2.2 litres--but no change after prednisone. Both medications produced significant and similar improvements in morning and evening Airflometer readings, post-bronchodilator improvement, and diurnal variation. Thus at doses that had similar beneficial effects on lung function beclomethasone dipropionate caused a significant improvement in bronchial hyperresponsiveness whereas prednisone caused no change. The superior topical anti-inflammatory effect of beclomethasone dipropionate may account for the different effects on bronchial hyperresponsiveness.
Topics: Administration, Inhalation; Administration, Oral; Adult; Asthma; Beclomethasone; Bronchi; Bronchial Provocation Tests; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Prednisone
PubMed: 3194866
DOI: 10.1136/thx.43.5.378 -
Postgraduate Medical Journal Apr 1972
Topics: Adult; Arthritis, Rheumatoid; Female; Gastrointestinal Hemorrhage; Humans; Prednisone; Scurvy
PubMed: 4538611
DOI: 10.1136/pgmj.48.558.243